Company news
Firebrick Pharma Limited (ASX:FRE) news
Firebrick Pharma Limited news releases on 6ix. Latest, Sep 28, 2026: Firebrick announces USA Retail Launch Plan
Press releases & updates
Firebrick announces USA Retail Launch Plan
September 28, 2026
Firebrick receives $293,000 R&D Tax Incentive
September 22, 2026
Appendix 4E and Annual Report 30 June 2026
August 31, 2026
Investor Update
July 26, 2026
March 2026 Quarterly Activity Report & Appendix 4C
April 21, 2026
Firebrick Secures $1.5 million via Placement
March 30, 2026
Trading Halt
March 26, 2026
Registration Agreement and Approval of Nasodine in Indonesia
March 26, 2026
Appendix 4D & Half-Year Financial Report to 31 December 2025
February 24, 2026
December 2025 Quarterly Activity Report & Appendix 4C
January 27, 2026
Nasodine Throat Spray Product Launch in Singapore
January 20, 2026
Firebrick announces new product Nasodine Throat Spray
October 29, 2025
September 2025 Quarterly Activity Report & Appendix 4C
October 22, 2025
Firebrick Secures Investment from Philippines Partner
October 15, 2025
Firebrick receives $250,000 R&D Tax Incentive
September 9, 2025
Appendix 4E and Annual Report 30 June 2025
August 29, 2025
Firebrick Secures $1.4 million via Placement
August 25, 2025
License Agreement for Singapore, Malaysia, Brunei, Mauritius
August 25, 2025
June 2025 Quarterly Activity Report & Appendix 4C
July 22, 2025
Firebrick Closes Placement at $0.2 milliion
June 25, 2025
Withdrawal of Share Placement
June 6, 2025
March 2025 Quarterly Activity Report & Appendix 4C
April 16, 2025
FRE secures Strategic Investment from Philippines Partner
March 3, 2025
Appendix 4D & Half-Year Financial Report to 31 December 2024
February 20, 2025
December 2024 Quarterly Activity Report & Appendix 4C
January 22, 2025
Nasodine Retail Pharmacy Launch in Singapore
November 24, 2024
Agreement Signed to Market Nasodine to HCPs in Singapore
October 30, 2024
September 2024 Quarterly Activity Report & Appendix 4C
October 22, 2024
Completion of Share Purchase Plan
October 9, 2024
Firebrick receives $0.9 million R&D Tax Incentive
September 22, 2024
Share Purchase Plan
September 11, 2024
Appendix 4E and Annual Report 30 June 2024
August 30, 2024
New agreement allows Nasodine launch in Philippines
August 14, 2024
June 2024 Quarterly Activity Report & Appendix 4C
July 29, 2024
Firebrick Launches Nasodine in Singapore
June 12, 2024
Firebrick Raises $800,000 via Placement
May 16, 2024
March 2024 Quarterly Activity Report & Appendix 4C
April 22, 2024
Nasodine Nasal Spray Launch in the USA
April 16, 2024
Appendix 4D & Half-Year Financial Report to 31 December 2023
February 28, 2024
December 2023 Quarterly Activity Report & Appendix 4C
January 23, 2024
Firebrick Investor Update
November 14, 2023
Firebrick Receives $1.81m R&D Tax Incentive
October 30, 2023
September 2023 Quarterly Activity Report & Appendix 4C
October 26, 2023
Update on Nasodine Trial and Forward Plans
October 2, 2023
Phase 3 Common Cold Trial Results
September 13, 2023
Appendix 4E & Annual Report FY23
August 29, 2023
Response to ASX Price and Volume Query
August 28, 2023
Firebrick Phase 3 Trial Closes with 500 Subjects
August 8, 2023
Firebrick Covid-19 Trial Achieves Primary Endpoint
August 6, 2023
June 2023 Quarterly Activity Report & Appendix 4C
July 26, 2023